Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Composite Steep-pulse Treatment for Benign Prostatic Hyperplasia
NCT05531344Phase 3Completed
- Sponsor
- REMD (睿刀医疗)
- Start
- Aug 2020
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by REMD (睿刀医疗). Primary endpoint: Maximum urinary flow rate at 3 months. Started Aug 2020; status: completed.
Beyond the preview
Go deeper on NCT05531344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05531344.